首頁
Mapp Biopharmaceutical

6月 2026Mapp Biopharmaceutical的市場佔有率分析

Public Release

行業: N/A

域名mappbio.com

成立年份2003

僱員51 - 200

年度營收$10M - $15M

Mapp Biopharmaceutical

Mapp Biopharmaceutical（包含公司地區）

mappbio.com

查看更多網站流量與參與度資訊

Mapp Biopharmaceutical截至 6月 2026 的總收入為 10M - 15M

Mapp Biopharmaceutical 熱門網域產生的總收入

Mapp Biopharmaceutical 熱門網域 3 年內的總收入

Mapp Biopharmaceutical 熱門網域的總收入

mappbio.com10M - 15M

透過銷售情報查看更多內容

Mapp Biopharmaceutical的熱門網域總造訪量

了解Mapp Biopharmaceutical市場觸達率與潛在市場影響力。

過去 3 個月的訪問總量

子公司細目

mappbio.com1.5K

透過銷售情報查看更多內容

Mapp Biopharmaceutical的熱門網域平均造訪時長

分析Mapp Biopharmaceutical參與度指標。

過去 3 個月平均造訪時長

子公司細目

mappbio.com00:01:03

透過銷售情報查看更多內容

Mapp Biopharmaceutical的熱門網域平均頁面瀏覽量

了解Mapp Biopharmaceutical如何保持使用者的參與度、培養其興趣，並鼓勵他們採取下一步。

過去 3 個月平均頁面瀏覽量

子公司細目

mappbio.com2.65

透過銷售情報查看更多內容

Mapp Biopharmaceutical按網域劃分的熱門競爭對手

6月 2026的熱門類似網站，依相似度排名

fortebio.com公司名ForteBio僱員51 - 200總部美國, 加利福尼亞, Fremont年度營收$25M - $50M訪問總量--科學與教育 > 生物學

使用的熱門技術Mapp Biopharmaceutical

这些是Mapp Biopharmaceutical顶级域名使用的行业网站技术

小工具 (4)

Twemoji

轉換與分析 (3)

Google Analytics

付費廣告 (2)

Google Adsense

內容管理系統 (2)

WordPress

更多技術

8

檢視所有

新聞與訊號來自Mapp Biopharmaceutical

透過 Similarweb 銷售訊號提醒，每當目標受眾出現新的機會或威脅時，你就會收到每日更新的已識別購買訊號。

新聞Mappbio recognized as leading therapeutic candidates..The WHO named Mapp Biopharmaceutical's MBP134, Regeneron's maftivimab, and Gilead Sciences' antiviral remdesivir as the leading therapeutic candidates.[1] The agency, working alongside outside experts, has been engaged in a broader effort to identify viable candidates for both treatment and prevention, a pressing task given that there are currently no approved vaccines or therapies specifically targeting Bundibugyo virus disease.[1]

新聞Mappbio partnered with Medical Countermeasures on May 11th '26.Mapp, which developed the antibody treatment ZMAPP during the 2014-2016 Ebola outbreak in West Africa, is working with the Biomedical Advanced Research and Development Authority, or BARDA, to supply the treatment for potential use in high-risk individuals, a U.S. official said on Wednesday.

新聞Mappbio is developing pan-ebolavirus antibody drug.Privately held Mapp Biopharmaceutical is developing a pan-ebolavirus antibody drug involving a combination of two human monoclonal antibodies, MBP134.